Q1 2026 · 13F-HR
Ally Bridge Group (NY) LLCholdings as filed
Filed 2026-05-18 · accession 0001193125-26-227559
$123.8M
Reported value
27
Positions
2026-03-31
Period end
The Brief · Ally Bridge Group (NY) LLC · Q1 2026
AI · grounded in 13F
Ally Bridge Group (NY) LLC closed its position in ATAI BECKLEY NV, reducing exposure by $7,006,599. The fund established new positions in TARS for $5,672,259 and CMPX for $5,290,000. Other activity included closing its position in TSHA for $5,264,226 and increasing its share count in SLNO by 138.05%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $10.6M | 8.54% | 32,810 | Common | SOLE |
| 603380205 | NERV | MINERVA NEUROSCIENCES INC | $10.0M | 8.06% | 1,655,500 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $6.7M | 5.41% | 200,000 | PUT | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $6.7M | 5.41% | 200,000 | Common | SOLE |
| 690469101 | OVID | OVID THERAPEUTICS INC | $6.3M | 5.05% | 2,818,459 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $5.8M | 4.67% | 1,045,000 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $5.7M | 4.58% | 80,859 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $5.5M | 4.46% | 766,974 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $5.3M | 4.27% | 1,000,000 | CALL | SOLE |
| 74346M505 | PMN | PROMIS NEUROSCIENCES INC | $5.3M | 4.25% | 414,219 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $5.1M | 4.10% | 161,000 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $4.9M | 3.96% | 300,000 | CALL | SOLE |
| 29842P105 | EPRX | EUPRAXIA PHARMACEUTICALS INC | $4.8M | 3.86% | 660,375 | Common | SOLE |
| 23284F105 | CTMX | CYTOMX THERAPEUTICS INC. | $4.2M | 3.42% | 900,000 | Common | SOLE |
| 46124U107 | IVA | INVENTIVA SA | $4.1M | 3.34% | 745,300 | Common | SOLE |
| 46489V302 | CATX | PERSPECTIVE THERAPEUTICS INC | $3.9M | 3.12% | 926,557 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $3.8M | 3.03% | 33,712 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC | $3.7M | 2.97% | 166,959 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $3.6M | 2.94% | 202,124 | Common | SOLE |
| 14070B309 | CAPR | CAPRICOR THERAPEUTICS INC | $3.5M | 2.80% | 113,899 | Common | SOLE |
| 578784100 | MAZE | MAZE THERAPEUTICS INC | $3.0M | 2.41% | 100,000 | CALL | SOLE |
| 00032Q104 | WHWK | WHITEHAWK THERAPEUTICS INC | $2.8M | 2.28% | 817,939 | Common | SOLE |
| 45719W205 | IKT | INHIBIKASE THERAPEUTICS INC | $2.2M | 1.80% | 1,325,000 | Common | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $1.9M | 1.53% | 246,900 | CALL | SOLE |
| 037326105 | ANTX | AN2 THERAPEUTICS INC | $1.8M | 1.45% | 526,315 | Common | SOLE |
| 75955J402 | RLMD | RELMADA THERAPEUTICS INC | $1.5M | 1.18% | 210,525 | Common | SOLE |
| 48576U205 | KPTI | KARYOPHARM THERAPEUTICS INC | $1.4M | 1.12% | 250,000 | CALL | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.